Lumigan eye drops 0.03% Allergan decreased in internal pressure (3ml)

Dosage form Bottle x 3ml
Specifications Bimatoprost

Ingredient

Thành phần cho 1ml

Composition information	Content
Bimatoprost	0.3mg

Uses

indications

Lumigan medicine is indicated in the following case:

Reduce the increased intraocular pressure in patients with Glaucoma open angle or glaucoma.

This substance selectively simplifies the effect of natural substance is prostamid. Bimatoprost is thought to lower the internal pressure (IOP) in humans by increasing the release of the raft (trabecular meshwork) and grape - enlisted membrane.

Interior pressure increases are the main risk of market loss due to glaucoma. The higher the level of internal pressure, the more likely it is to damage the optic nerves and cause the market loss.

Dynamic pharmacokinetics

absorption

After dripping a small drop of bimatoprost eye solution 0.03% 1 time/day on both eyes for two weeks, the peak concentration in the blood is reached after the small 10 minutes lower than the lower limit can be detected (0.025 ng/ml) within 1.5 hours after eye drops. The average peak concentration value is 0.08 ng/ml and bioavailability is 0.09 ng.Vent/ml equivalent on Saturday and 14th day, showing that it has achieved a stable state in the first week of small drugs. There is no significant body accumulation during the research period.

distribution

Bimatoprost is moderately distributed into the body tissue with the volume of distribution in a stable state of 0.67 l/kg. In human blood, bimatoprost exists mainly in plasma. About 12% bimatoprost does not attach to human plasma.

transformation

After small eyes, bimatoprost is the main circulation in the blood when entering the whole body. Bimatoprost will then be metabolized through oxidation reactions, n-ethyl, glucuronid complexes to form different metabolites.

Elimination

After intravenous injection, the peak concentration of the drug is constant of 12.2 ng/ml and rapidly decreases with a half -life of about 45 minutes. The total bimatoprost clearance in the blood is 1.5 l/h/kg. About 67% of the dosage excreted through the urine, 25% of the dose excreted through feces.

Before taking Lumigan eye drops 0.03% Allergan decreased in internal pressure (3ml)

How to use

Lumigan drugs are used in the eyes, 1 time/day in the evening.

Dosage

recommended dose is a drop of 1 drop into the eyes, 1 time/day in the evening.

Lumigan dose of 0.01% should not exceed 1 time/day because it has been recorded as small times similar to prostaglandin, reducing the effect of lowering internal pressure.

The reduction of internal pressure starts about 4 hours after the first time, the multi -effect effect is about 8 - 12 hours.

Lumigan 0.01% can be used simultaneously with other eye drops to lower internal pressure. If you use more than a small eye drop, the drugs must be spaced at least 5 minutes apart.

It is not recommended to use in children under 16 years of age because it is related to increased pigmentation when used for a long time in chronic diseases.

Not observing any overall difference in safety or effectiveness between old patients and young patients.

In patients with a history of liver disease or ALT, abnormal AST and/or bilirubin at the basic level, 0.03% bimatoprost does not adversely affect liver function within 48 months.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

If the overdose of Lumigan is 0.01%, it is necessary to treat symptoms.

In Vivo studies, oral doses of up to 100 mg/kg/day did not cause any toxicity. By mg/m2, this dose is at least 160 times higher than the toxic dose of 0.01% Lumigan vial for a child weighing 10kg.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Do not drink twice as prescribed.

Side Effects

Unwanted effects when using Lumigan that you may encounter.

Common, ADR> 1/100

Eyes: Eye irritation, eyelid red rash, Itchy eye , eyelid itching, lashic hyperplasia, Palatitis shallow spots.

Skin and subcutaneous tissue: him, hyperpigmentation, small irritation of drugs.

Not determined frequency

Eyes: eye pain.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

for patients with hypersensitivity to bimatoprost or any ingredient of the drug.

Be cautious when using

Divinity

Bimatoprost small eye solution may alter pigment tissues. The most common is to increase the pacifier in the iris, the tissue around the eye (eyelid) and eyelashes. The pigment is expected to increase while using bimatoprost.

The change in pigmentation is due to increasing the amount of melanin (pigmentation) in the epidermis to form pigmentation rather than an increase in the number of pigment cells.

After stopping the use of bimatoprost, changing pigmentation in the iris can last long, while changing the pigment in the tissue around the eye and eyelashes can recover in some patients. The patient must be notified of the possibility of increased pigmentation may be permanent.

The long -term impact of hyperpigmentation is not well known.

The color change of iris may not be detected for months to many years. Typically, the brown pigment around the pupils, spreading in the shape of a concentric towards the peripheral of the iris, and the whole or part of the iris becomes brown.

Small brown spots of iris are not affected by treatment.

While 0.01% Lumigan treatment may continue to give patients with increased pigmentation in the iris but need to be checked regularly.

Mi eyelash changes

Lumigan 0.01% may gradually change the eyelashes, the eyes in the eye are treated, including increasing length, thickness, and the amount of eyelashes. Before starting treatment, it is necessary to notify the patient about this possibility. These changes often recover when stopped.

Eye inflammation

Lumigan 0.01% should be used carefully in patients with inflammation in the eye (grape veins) because inflammation may be worse.

point

The royal point, including the follicle -shaped point, was recorded during the treatment of bimatoprost eye solution.

Be careful when using 0.01% Lumigan for patients without a lens, patients use fake lens with the following covers of torn or in patients who know that there is a risk of throttle (intraocular surgery, retinal vein obstruction, eye inflammation and diabetic retinopathy).

glaucoma

Not yet evaluated the effect of 0.01% Lumigan in the treatment of closed angle glaucoma, inflammation Glaucoma or glaucoma new vessel.

bacterial keratitis

There has been a report on this situation related to the use of multi -dose eye drops. The vial of the patient is unintentionally contaminated and in most cases of corneal disease. Patients who have a higher risk of the epithelium of the eye are at a higher risk of bacterial keratitis.

used when wearing contact lenses

contact lenses must be removed before 0.01% Lumigan medicine and 15 minutes after finishing, can wear glasses.

The ability to drive and operate machinery

as well as with any small eye preparation, if the glimpse is faded at a small drug, the patient should wait until it is clear before driving or using machines.

Pregnancy

group

The teratogenic effect:

In Vivo studies, there is a miscarriage when taking Bimatoprost doses at least 33 times in mice and 97 times in mice compared to the dosage on humans. With a dose of 41 times the dose in humans, the length of pregnancy is reduced in the mother rat, the rate of pregnancy, the rate of failure after the embryo transplantation, the mortality rate in the child has not given birth and after birth increases, the weight of the child is reduced.

There is no adequate and well -controlled research on the use of 0.01% Lumigan for pregnant women, only 0.01% Lumigan should be used in pregnancy if the benefits of using drugs for mothers are higher than the risk that may be available to the fetus.

The period of breastfeeding

In vivo research shows that Bimatoprost is excreted through the mother's milk, but it is unclear whether the drug is excreted through human milk. Be careful when using Lumigan 0.01 % for breastfeeding women.

Drug interaction

is not sure to have drug interactions in humans due to the low concentration of bimatoprost (below 0.2 ng/ml) during the whole week of the body after the bimatoprost dose of 0.03%.

Bimatoprost has been shifted in a biological form in many enzymes and many ways, and there is no effect on drug metabolic yeasts in the liver, which has been observed in preclinical studies on mice and monkeys.

In clinical studies, 0.03% (multi -dose) Lumigan eye solution has been used simultaneously with some beta blockers without any evidence of interaction.

Shared Lumigan use 0.01% with eye drops Glaucoma is not a beta inhibitor that has not been evaluated in Glaucoma therapy.

The effect of reducing the internal pressure (IOP) of prostaglandin (lumigan) substances can be reduced in patients with glaucoma or glaucoma when used with other substances similar to prostaglandin.

Storage

Storage below 30 ° C. Do not use more than 4 weeks after opening.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.